Watch AQST. Know when insiders buy.
One email the day a filing lands. Free.
AQST
Aquestive Therapeutics, Inc.
5.34
−0.01 −0.19%
USD · close Sep 4
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
15
FLAG · shorts 15
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $670.2MP/E —DIV YIELD —FCF YIELD -6.86%REV TTM $54.1M +22.6%NET INCOME −$78.2MNET CASH $43.5M52W 2.95 – 7.49SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $13.8M | +38.1% | 70.9% | −$8.2M | −$22.9M | — | -0.18 | −$9.4M | $212K | −$9.7M | Aug 11 |
| Q1 2026 · Mar 31 | $14.4M | +65.7% | 76.0% | −$4.2M | −$8.1M | — | -0.07 | −$14.8M | $52K | −$14.9M | Aug 11 |
| Q4 2025 · Dec 31derived | $13M | +9.7% | 55.2% | −$28.8M | −$31.9M | — | -0.27 | −$8.5M | $85K | −$8.6M | Mar 4 |
| Q3 2025 · Sep 30 | $12.8M | −5.4% | 64.8% | −$11.5M | −$15.4M | — | -0.14 | −$12.6M | $235K | −$12.9M | Nov 5 |
| Q2 2025 · Jun 30 | $10M | −50.2% | 54.4% | −$11.4M | −$13.5M | — | -0.14 | −$7.9M | $107K | −$8M | Aug 11 |
| Q1 2025 · Mar 31 | $8.7M | −27.7% | 58.1% | −$19.4M | −$22.9M | — | -0.24 | −$23.4M | $135K | −$23.5M | Aug 11 |
| Q4 2024 · Dec 31derived | $11.9M | −10.1% | 61.9% | −$13.6M | −$17.1M | — | -0.19 | −$6.5M | $15K | −$6.5M | Mar 4 |
| Q3 2024 · Sep 30 | $13.5M | +4.2% | 67.2% | −$8.3M | −$11.5M | — | -0.13 | −$11.9M | $80K | −$12M | Nov 5 |
| Q2 2024 · Jun 30 | $20.1M | — | 77.5% | $55K | −$2.7M | — | -0.03 | −$7M | $35K | −$7M | Nov 5 |
| Q1 2024 · Mar 31 | $12.1M | — | 63.6% | −$9M | −$12.8M | — | -0.17 | −$10.4M | $29K | −$10.4M | Nov 5 |
| Q4 2023 · Dec 31derived | $13.2M | — | 64.6% | −$3.9M | −$8.1M | — | -0.13 | −$4.9M | $16K | −$5M | Mar 5 |
| Q3 2023 · Sep 30 | $13M | — | 63.1% | −$2.4M | −$2M | — | -0.03 | −$2.3M | $151K | −$2.5M | Nov 4 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $44.5M | 58.3% | −$71.1M | −$83.8M | -188.1% | -0.78 | −$52.4M | $562K | −$53M | — | — |
| FY2024 · to Dec 31 | $57.6M | 69.0% | −$30.8M | −$44.1M | -76.7% | -0.51 | −$35.8M | $159K | −$35.9M | — | — |
| FY2023 · to Dec 31 | $50.6M | 58.8% | −$15.1M | −$7.9M | -15.6% | -0.13 | −$6.4M | $995K | −$7.4M | — | — |
| FY2022 · to Dec 31 | $47.7M | 59.3% | −$42.1M | −$54.4M | -114.1% | -1.12 | −$9.8M | $1M | −$10.8M | — | — |
| FY2021 · to Dec 31 | $50.8M | — | −$34.7M | −$70.5M | -138.8% | -1.85 | −$33M | $913K | −$33.9M | — | — |
| FY2020 · to Dec 31 | $45.8M | 71.7% | −$42.9M | −$55.8M | -121.7% | -1.66 | −$45.5M | $517K | −$46M | — | — |
Every number comes from Aquestive Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.